(Level of Evidence: A) The duration and maintenance dose of P2Y12 receptor inhibitor therapy should be as follows: modified (included the term P2Y12 receptor inhibitor and altered aspirin dosing and duration of therapy after stent deployment). a. Clopidogrel 75 mg daily,16 prasugrel 10 mg daily,7 or ticagrelor 90 mg twice daily9 should be given for at least 12 months in patients receiving DES and up to 12 months for patients receiving BMS.9,13,16 (Level of Evidence: B) b. If the risk of morbidity because of bleeding outweighs the anticipated benefits afforded by P2Y12 receptor inhibitor therapy, earlier discontinuation should be considered. (Level of Evidence: C) 3. Clopidogrel 75 mg daily13,67 (Level of Evidence: B), prasugrel 10 mg daily (in PCI-treated patients)7 (Level of Evidence: C), or ticagrelor 90 mg twice daily9 (Level of Evidence: C) should be given to patients recovering from UA/NSTEMI when aspirin is contraindicated or not tolerated because of hypersensitivity or GI intolerance (despite use of gastroprotective agents such as PPIs).42,68 modified (included prasugrel and ticagrelor; deleted ticlopidine). Class IIa 1. After PCI, it is reasonable to use 81 mg per day of aspirin in preference to higher maintenance doses.32,33,90,127,128 (Level of Evidence: B) modified (changed wording and aspirin dose to be concordant with the 2011 PCI guideline75). Class IIb 1. For UA/NSTEMI patients who have an indication for anticoagulation, the addition of warfarin may be reasonable to maintain an INR of 2.0 to 3.0. 129 138 (Level of Evidence: B) 2007 recommendation remains current. 2. Continuation of a P2Y12 receptor inhibitor beyond 12 months may be considered in patients following DES placement. (Level of Evidence: C) modified (changed time period to be concordant with 2011 PCI guideline75 and replaced clopidogrel and prasugrel with P2Y12 receptor inhibitor ). Class III: No Benefit 1. 